Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status

Clinical Endocrinology

Volumn 80, Issue 1, 2014, Pages 57-64

  Lee, Yenna ^a,b   Lim, Soo ^a,b   Hong, Eun Shil ^a,b   Kim, Jung Hee ^b   Moon, Min Kyung ^a   Chun, Eun Ju ^a   Choi, Sang Il ^a   Kim, Young Bum ^c   Park, Young Joo ^a   Park, Kyong Soo ^a   Jang, Hak C ^a,b   Choi, Sung Hee ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBESITY; PERICARDIUM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PERICARDIUM;

EID: 84889591200     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12134     Document Type: Article

References (43)

1. Badman, M.K., Pissios, P., Kennedy, A.R., et al,. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism, 5, 426-437.
2. Inagaki, T., Dutchak, P., Zhao, G., et al,. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism, 5, 415-425.
3. Potthoff, M.J., Inagaki, T., Satapati, S., et al,. (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences, USA, 106, 10853-10858.
4. Nishimura, T., Nakatake, Y., Konishi, M., et al,. (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta, 1492, 203-206.
5. Kharitonenkov, A., Shiyanova, T.L., Koester, A., et al,. (2005) FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115, 1627-1635.
6. Mraz, M., Bartlova, M., Lacinova, Z., et al,. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clinical Endocrinology, 71, 369-375.
7. Izumiya, Y., Bina, H.A., Ouchi, N., et al,. (2008) FGF21 is an Akt-regulated myokine. FEBS Letters, 582, 3805-3810.
8. Arner, P., Pettersson, A., Mitchell, P.J., et al,. (2008) FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Letters, 582, 1725-1730.
9. Xiao, Y., Xu, A., Law, L.S., et al,. (2012) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. Journal of Clinical Endocrinology and Metabolism, 97, E54-E58.
10. Coskun, T., Bina, H.A., Schneider, M.A., et al,. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149, 6018-6027.
11. Kharitonenkov, A., Wroblewski, V.J., Koester, A., et al,. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148, 774-781.
12. Xu, J., Lloyd, D.J., Hale, C., et al,. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 58, 250-259.
13. Chen, W.W., Li, L., Yang, G.Y., et al,. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 116, 65-68.
14. Eto, K., Tumenbayar, B., Nagashima, S., et al,. (2010) Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 89, 52-57.
15. Mai, K., Schwarz, F., Bobbert, T., et al,. (2011) Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism, 60, 306-311.
16. Zhang, X., Yeung, D.C., Karpisek, M., et al,. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 1246-1253.
17. Stein, S., Bachmann, A., Lossner, U., et al,. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32, 126-128.
18. Han, S.H., Choi, S.H., Cho, B.J., et al,. (2010) Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism, 59, 1656-1662.
19. Dushay, J., Chui, P.C., Gopalakrishnan, G.S., et al,. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 139, 456-463.
20. Li, H., Fang, Q., Gao, F., et al,. (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, 53, 934-940.
21. Tyynismaa, H., Raivio, T., Hakkarainen, A., et al,. (2011) Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. Journal of Clinical Endocrinology and Metabolism, 96, E351-E355.
22. Lin, Z., Wu, Z., Yin, X., et al,. (2011) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE, 5, e15534.
23. Kim, T.H., Yu, S.H., Choi, S.H., et al,. (2010) Pericardial fat amount is an independent risk factor of coronary artery stenosis assessed by multidetector-row computed tomography: The Korean Atherosclerosis Study 2. Obesity (Silver Spring), 19, 1028-1034.
24. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al,. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
25. Lim, S., Choi, S.H., Choi, E.K., et al,. (2009) Comprehensive evaluation of coronary arteries by multidetector-row cardiac computed tomography according to the glucose level of asymptomatic individuals. Atherosclerosis, 205, 156-162.
26. Austen, W.G., Edwards, J.E., Frye, R.L., et al,. (1975) A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery. American Heart Association. Circulation, 51, 5-40.
27. Hausleiter, J., Meyer, T., Hadamitzky, M., et al,. (2006) Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. Journal of the American College of Cardiology, 48, 312-318.
28. Agatston, A.S., Janowitz, W.R., Hildner, F.J., et al,. (1990) Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology, 15, 827-832.
29. Rybicki, F.J., (2011) Coronary flow dynamics measured by computed tomography angiography. Journal of the American College of Cardiology, 57, 1289-1290.
30. American Diabetes Association (2011) Standards of medical care in diabetes-2011. Diabetes Care, 34, S11-S61.
31. Region, W.W.P., (2000) The Asia-Pacific Perspective: redefining obesity and its treatment. International Obesity Task Force, 2, 15-21.
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
33. Moyers, J.S., Shiyanova, T.L., Mehrbod, F., et al,. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. Journal of Cellular Physiology, 210, 1-6.
34. Zhang, Y., Lei, T., Huang, J.F., et al,. (2011) The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Molecular and Cellular Endocrinology, 342, 41-47.
35. Mashili, F.L., Austin, R.L., Deshmukh, A.S., et al,. (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes/Metabolism Research and Reviews, 27, 286-297.
36. An, S.Y., Lee, M.S., Yi, S.A., et al,. (2012) Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Research and Clinical Practice, 96, 196-203.
37. Reinehr, T., Woelfle, J., Wunsch, R., et al,. (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. Journal of Clinical Endocrinology and Metabolism, 97, 2143-2150.
38. Yan, H., Xia, M., Chang, X., et al,. (2011) Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS ONE, 6, e24895.
39. Sicari, R., Sironi, A.M., Petz, R., et al,. (2011) Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. Journal of the American Society of Echocardiography, 24, 1156-1162.
40. Rosito, G.A., Massaro, J.M., Hoffmann, U., et al,. (2008) Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation, 117, 605-613.
41. Mahabadi, A.A., Massaro, J.M., Rosito, G.A., et al,. (2009) Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. European Heart Journal, 30, 850-856.
42. Iozzo, P., Lautamaki, R., Borra, R., et al,. (2009) Contribution of glucose tolerance and gender to cardiac adiposity. Journal of Clinical Endocrinology and Metabolism, 94, 4472-4482.
43. Fisher, F.M., Chui, P.C., Antonellis, P.J., et al,. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 59, 2781-2789.